利拉鲁肽极化M2型巨噬细胞改善非酒精性脂肪肝的机制

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1636 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the potential mechanism of liraglutide in improving nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes. Methods: A mouse model of type 2 diabetes with NAFLD was constructed by high-sugar and high-fat diet with a low dose streptozoticin. The mice were randomly divided into 3 groups, normal group, model group and liraglutide group, with 15 mice in each group. The mice in liraglutide group were injected subcutaneously with liraglutide (100 μg/kg) once a day, lasting for 4 weeks. Body weight of each mouse and their liver index, ALT, AST and TG were measured. Pathological changes of liver tissue were observed by HE staining and oil red “O” staining. The levels of interleukin-4 (IL-4) and IL-10 in serum were detected by ELISA. The proportion of M2 macrophages was detected by flow cytometry. The expressions of IL-4, IL-10, CD206, CD301, MGL-1, MGL-2 and arginine-1 mRNA were examined using RT-PCR. Results: Compared with the model group, the body weight, liver index, TG, AST and ALT of the mice in liraglutide group were decreased significantly, the fatty degeneration in the liver tissue was down-regulated, while the proportion of M2 macrophages had an obvious rise (P<0.001), and the expressions of IL-4 and IL-10 were increased notably (P<0.05). Additionally, the expressions of IL-4, IL-10, CD206, CD301, MGL-1, MGL-2 and Arg-1 mRNA were significantly up-regulated in liraglutide group (P<0.01). Conclusion: Liraglutide has protective effect on NAFLD in type 2 diabetes, possibly by promoting the expression of IL-4 and IL-10 to polarize M2 macrophages so that the mechanism of NAFLD get improved.

Key words： liraglutide macrophage nonalcoholic fatty liver mice

Received: 07 March 2019

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIANG Xiaomei
	LIU Chong.

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2019/V49/I9/661

[1] WILLIAMSON R M, PRICE J F, GLANCY S, et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes[J]. Diabetes Care, 2015, 34(5): 1139-1144.
[2] 洪逸莲, 顾雪疆, 徐静, 等. 人参皂苷Rb2对高脂性脂肪肝小鼠肝脏脂质代谢的影响及其机制 [J]. 温州医科大学学报, 2018, 48(5): 338-341, 349.
[3] 董志霞, 陆伦根. 2015 JSGE非酒精性脂肪性肝病/非酒精性脂肪性肝炎循证临床实践指南解读[J]. 中国医学前沿杂志(电子版), 2015, 7(4): 19-22.
[4] 曾志刚, 徐丽姝, 关丽嫦, 等. 利拉鲁肽对非酒精性脂肪肝大鼠脂联素及胰岛素抵抗的影响[J]. 中国病理生理杂志, 2014, 30(3): 533-537.
[5] 陈左平. 利拉鲁肽治疗2型糖尿病合并轻中度慢性肾脏病的有效性和安全性分析[J]. 中国当代医药, 2016, 23(30): 131-133.
[6] MANTOVANI A, BISWAS S K, GALDIERO M R, et al. Macrophage plasticity and polarization in tissue repair and remodelling[J]. J Pathol, 2013, 229(2): 176-185.
[7] WYNN T A, AJAY C, POLLARD J W. Macrophage biology in development, homeostasis and disease[J]. Nature, 2013, 496(7446): 445-455.
[8] 况晓东, 周晓燕, 艾有生. 巨噬细胞极化与代谢性疾病的研究进展[J]. 实用临床医学, 2012, 13(4): 123-125, 129.
[9] KAPLAN M, AVIRAM M, HAYEK T. Oxidative stress and macrophage foam cell formation during diabetes mellitus-induced atherogenesis: role of insulin therapy[J]. Pharmacol Ther, 2012, 136(2): 175-185.
[10] 叶启宝, 何媛媛, 吕齐欢, 等. 利拉鲁肽治疗2型糖尿病合并非酒精性脂肪肝患者的临床观察[J]. 医学研究杂志, 2015, 44(7): 152-154.
[11] TIAN F, ZHENG Z, ZHANG D, et al. Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease[J]. Biosci Rep, 2018, 38(6).pii: BSR20181304.
[12] RAHMAN K, LIU Y, KUMAR P, et al. C/EBP homologous protein modulates liraglutide-mediated attenuation of non-alcoholic steatohepatitis[J]. Lab Invest, 2016, 96(8): 895-908.
[13] SAPONARO C, GAGGINI M, GASTALDELLI A. Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms[J]. Curr Diab Rep, 2015, 15(6): 607-620.
[14] 邢英, 李雅丽, 郑嵘炅, 等. 利拉鲁肽对非酒精性脂肪肝大鼠胰岛素抵抗的改善作用[J]. 实用肝脏病杂志, 2017, 20(6): 30-33.
[15] EGUCHI Y, KITAJIMA Y, HYOGO H, et al. Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)[J]. Hepatol Res, 2015, 45(3): 269-278.
[16] WAN J, BENKDANE M, TEIXEIRA-CLERC F, et al. M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease[J]. Hepatology, 2014, 59(1): 130-142.
[17] 廖海林. 甘油三酯在非酒精性脂肪肝沉积的机制研究进展[J]. 临床与病理杂志, 2014, 34(6): 831-836.
[18] 田希贵, 刘德森, 汪元玉, 等. 腺癌与其他类型非小细胞肺癌术后临床特点的差异及预后因素分析[J]. 中国癌症杂志, 2017, 27(3): 227-232.
[19] 邵小娟, 陈东风. 肝脏巨噬细胞极化与非酒精性脂肪性肝病的关系[J]. 胃肠病学和肝病学杂志, 2013, 22(3): 205-207.
[20] MAINA V, SUTTI S, LOCATELLI I, et al. Bias in macrophage activation pattern influences non-alcoholic steatohepatitis (NASH) in mice [J]. Clin Sci, 2012, 122(11): 545-553.
[21] 侯洪涛, 冯佳, 裘艳梅, 等. 利拉鲁肽1对非酒精性脂肪肝大鼠及细胞因子的影响[J]. 中国现代医学杂志, 2017, 27(19): 7-11.
[22] 马卫德, 赵殿元, 唐丽. 肝脏巨噬细胞的研究进展[J]. 细胞与分子免疫学杂志, 2016, 32(2): 258-260.